[A21-51] Olaparib (prostate cancer) - Addendum to Commission A20-106

Last updated 04.06.2021

Project no.:
A21-51

Commission:
Commission awarded on 27.04.2021 by the Federal Joint Committee (G-BA).

Report type:
Addendum

Status:
Commission completed

Department/Division:
Drug Assessment

Topic:
Cancer

Indication:

Adult patients with metastatic castration-resistant prostate cancer and BRCA1/2-mutations (germline and/or somatic) who have progressed following prior therapy that included a new hormonal agent

Result of dossier assessment:

Patients for whom abiraterone or enzalutamide is the best individual choice: hint of considerable added benefit.

Patients for whom docetaxel or cabazitaxel is the best individual choice: added benefit not proven.

Note:

If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.

Federal Joint Committee (G-BA)

2021.06.04 A G-BA decision was published.

G-BA documents on this decision

Contact

Info Service (German)

Subscribe to daily updated information on projects, calls for tender, current vacancies and events as well as our press releases.

Register

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.

Contact form